UNSPSC 51352311: Estrazinol hydrobromide

This classification denotes a selective estrogen receptor modulator with the molecular formula C20H25NO2.BRH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P1NC244SOF. The term estrazinol hydrobromide is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule estrazinol hydrobromide under HS 29372300 and SITC 54153. As of Q4 2014, ESTRAZINOL HYDROBROMIDE remains US FDA's Preferred Term for this commodity.

Estrazinol hydrobromide bears US NLM identifiers UMLS ID C2700020 and NCI Concept Code C74403. SMILES: C[C@]12CC[C@@H]3C4CCC(CC4CCN3[C@@H]1CC[C@]2(C#C)O)OC.BR.

UNSPSC 51352311 Estrazinol hydrobromide (Commodity) encompasses pharmaceutical manufacturing and supply agreements for generic multi-source drugs distributed through state and local government procurement networks. The recent activity under this code involves cooperative purchasing arrangements where state and local agencies source generic pharmaceuticals and over-the-counter products through established wholesaler networks, with vendors required to maintain cGMP certification, Drug Supply Chain Security Act compliance, and pricing flexibility across multiple net-price and WAC-minus formats. Issuing bodies include multistate purchasing cooperatives and their participating member jurisdictions—primarily state health and human services departments, counties, municipalities, and other government facilities that source pharmaceuticals as part of routine operations. The procurement emphasizes competitive pricing (weighted at 75 percent of evaluation), administrative compliance with electronic data interchange capabilities, and contractual relationships with authorized wholesalers operating chargeback systems.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP (S1070000015802) on January 20, 2026, for generic multi-source pharmaceuticals and OTC products with a proposal deadline of March 26, 2026. The scope spans participating state and local government facilities across multiple states including Oregon and Minnesota, with awarded vendors expected to provide comprehensive product information by National Drug Codes and supply through AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC. Contract awards are effective July 1, 2026, with a two-year initial term and optional extensions. Vendors must carry commercial general liability insurance of $5,000,000 per occurrence, network security and privacy liability of $2,000,000, and professional liability of $2,000,000, and face performance penalties ranging from $200 to $1,500 per violation. No specific dollar value or set-aside designations were disclosed in the solicitation.